Genedrive (LSE:GDR) reported interim results for the period to 31 December 2025 showing higher revenue alongside a broadly unchanged operating loss, as the company continues investing in the commercial rollout of its CYP2C19 and MT-RNR1 pharmacogenetic tests in the UK and international markets. The group has gained access to several key NHS procurement and implementation channels, including formal guidance pathways, the Dynamic Procurement System and a range of pilot and rollout programmes across England, Scotland, Ireland and Saudi Arabia. These initiatives support its strategy to integrate rapid genetic testing into routine clinical pathways for stroke treatment and neonatal care.
Operationally, the CYP2C19 ID Kit is now deployed at England’s largest hyper-acute stroke unit and is also being evaluated through “test of change” pilot programmes in Scotland. A separate 12-month study is exploring its use in acute coronary syndrome, while the company is preparing for international market expansion and assessing the pathway toward U.S. FDA 510(k) clearance. Meanwhile, the MT-RNR1 ID Kit is currently used in 14 UK hospitals as part of the PALOH UK programme and forms part of a phased national rollout in Scotland. The test has also been introduced at Dublin’s Rotunda Hospital and will be evaluated through a national pilot programme in Saudi Arabia, helping generate real-world evidence to support broader adoption.
From a financial perspective, Genedrive strengthened its balance sheet through a post-period equity raise that generated around £4.9m net proceeds, alongside the conversion of a £0.5m shareholder loan into equity. As of 27 March 2026, the company reported cash of £3.65m, up from £0.4m at the end of the reporting period, and stated that it is now debt free. Management said the improved financial position will support FDA submission work, manufacturing scale-up, product usability enhancements and further international regulatory approvals as the company aims to transition from early commercial activity to more scalable revenues, despite ongoing NHS funding pressures.
The company’s outlook remains constrained by weak financial fundamentals, including continued losses, ongoing cash burn and a reduced equity base. Technical indicators offer some support, with the share price trading above key moving averages and showing positive MACD momentum, although an elevated RSI suggests the possibility of short-term overheating. Valuation remains challenging due to negative earnings and the absence of a positive price-to-earnings ratio.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic diagnostics company focused on rapid, point-of-care testing designed to guide safer and more effective medication use in emergency and acute care settings. Its CE-IVD approved and NICE-recommended Genedrive CYP2C19 and MT-RNR1 ID Kits are already used within the NHS, helping determine stroke patients’ response to the drug Clopidogrel and preventing antibiotic-related hearing loss in newborns. The company’s strategy centres on scaling UK-developed precision diagnostic technologies and expanding their adoption internationally.
Leave a Reply